![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ARGFX |
Gene summary for ARGFX |
![]() |
Gene information | Species | Human | Gene symbol | ARGFX | Gene ID | 503582 |
Gene name | arginine-fifty homeobox | |
Gene Alias | ARGFX | |
Cytomap | 3q13.33 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A6NJG6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
503582 | ARGFX | HCC1 | Human | Liver | HCC | 2.91e-18 | 1.46e+00 | 0.5336 |
503582 | ARGFX | HCC2 | Human | Liver | HCC | 3.94e-24 | 1.37e+00 | 0.5341 |
503582 | ARGFX | HCC5 | Human | Liver | HCC | 1.99e-22 | 1.46e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARGFX | SNV | Missense_Mutation | c.895N>C | p.Asp299His | p.D299H | A6NJG6 | protein_coding | deleterious(0.05) | possibly_damaging(0.84) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
ARGFX | SNV | Missense_Mutation | novel | c.393N>G | p.Phe131Leu | p.F131L | A6NJG6 | protein_coding | tolerated(0.23) | benign(0.35) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARGFX | SNV | Missense_Mutation | c.389N>A | p.Arg130Gln | p.R130Q | A6NJG6 | protein_coding | tolerated(0.1) | benign(0.235) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ARGFX | SNV | Missense_Mutation | rs777806670 | c.341N>A | p.Arg114Lys | p.R114K | A6NJG6 | protein_coding | tolerated(1) | benign(0) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
ARGFX | SNV | Missense_Mutation | c.402N>C | p.Lys134Asn | p.K134N | A6NJG6 | protein_coding | deleterious(0.01) | possibly_damaging(0.619) | TCGA-JW-A5VJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
ARGFX | SNV | Missense_Mutation | c.533N>T | p.Ser178Phe | p.S178F | A6NJG6 | protein_coding | tolerated(0.09) | benign(0.031) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ARGFX | SNV | Missense_Mutation | c.591G>T | p.Glu197Asp | p.E197D | A6NJG6 | protein_coding | tolerated(0.47) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
ARGFX | SNV | Missense_Mutation | rs768453486 | c.943N>A | p.Leu315Ile | p.L315I | A6NJG6 | protein_coding | deleterious_low_confidence(0) | benign(0.224) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ARGFX | SNV | Missense_Mutation | novel | c.596N>A | p.Ser199Tyr | p.S199Y | A6NJG6 | protein_coding | deleterious(0) | benign(0.094) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARGFX | SNV | Missense_Mutation | novel | c.839N>A | p.Pro280His | p.P280H | A6NJG6 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |